Icosapent ethyl use in clinical practice: current and future directions

Br J Cardiol 2023;30(suppl 2):S19–S21doi:10.5837/bjc.2023.s09 Leave a comment
Click any image to enlarge
Sponsorship Statement: Amarin UK Limited has funded this supplement through an independent grant and has had no control or input into the education content of this activity. Editorial and content decisions were made solely by the BJC.

Icosapent ethyl has been found to improve cardiovascular (CV) disease risk in high-risk patients when added to statin treatment; it has received regulatory clearance and recently, National Institute of Health and Care Excellence (NICE) approval1 to be used in the UK for selected patients with hypertriglyceridaemia. There are currently limited treatment options available to reduce the risk of CV events in people with controlled levels of low-density lipoprotein-cholesterol (on a statin) and raised triglyceride levels.


Originally, icosapent ethyl (IPE) was developed as a treatment for hypertriglyceridaemia.2 However, in the Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial (REDUCE-IT),3 IPE significantly decreased the risk of ischaemic events (including cardiovascular [CV] death) by ~25% after a median follow-up of 4.9 years. The study included patients with fasting triglyceride (TG) levels of 1.7 to 5.6 mmol/L (150 to 499 mg/dL) and low-density lipoprotein cholesterol (LDL-C) levels of 1.1 to 2.6 mmol/L (41 to 100 mg/dL) who were on optimum statin treatment. Interestingly, this reduction in CV risk was independent of TG lowering. This opened up the discussion about the possible mechanisms behind the risk-lowering effects of the drug.3

Based on the results of REDUCE-IT, IPE is generally well tolerated, with a similar distribution of people between the two groups (IPE [81.8%] and mineral oil placebo [81.3%]) reporting adverse events, except in the case of atrial fibrillation and peripheral oedema, which was significantly higher in the IPE group than the placebo group. However, in the IPE group, there was a significant reduction in the rates of anaemia, diarrhoea and gastrointestinal adverse events.1,3

Icosapent ethyl use in clinical practice: current and future directions

IPE and cardiovascular risk reduction: what’s next?

IPE affects lipids by increasing the activity of lipoprotein lipase and decreasing liver lipogenesis.4 However, IPE also has well-known anti-inflammatory properties,5 and CV risk reduction in REDUCE-IT3 was more related to the reduction of anti-inflammatory markers rather than triglyceride lowering. Therefore, it is likely that IPE may be targeting the residual inflammatory risk, although this hypothesis needs to be proven by prospective studies that will evaluate the impact of IPE on coronary vessel inflammation. Importantly, the use of mineral oil as the placebo in REDUCE-IT and the increased event rate observed in the placebo group of the trial has raised the question of whether the observed benefit of IPE was enhanced by the potentially detrimental effect of the placebo treatment. This makes the mechanistic investigation of IPE’s CV effects even more imperative.

Cardiovascular inflammation assessment

Cardiovascular inflammation can be evaluated either by measuring less specific, but easy to apply, surrogate circulating biomarkers (e.g., high-sensitivity C-reactive protein [hsCRP]) or by using more sophisticated imaging methods like positron emission tomography or computed tomography.6 Indeed, a recently developed imaging method utilises attenuation indexing of the perivascular adipose tissue from coronary computed tomography angiography images, to generate a quantitative metric of coronary inflammation, the fat attenuation index (FAI)7,8 and the respective FAI Score.9 The FAI and FAI Score capture the residual inflammatory risk10 and can be used to monitor responsiveness of coronary inflammation (and the associated risk) to treatments.11 Upcoming clinical trials are expected to evaluate the responsiveness of coronary inflammation and the residual inflammatory risk to IPE treatment in the near future.

Expanding the indications of IPE use

Another open question that needs addressing, is that of the rather restrictive indications for the use of IPE in the UK. Indeed, the NICE guidance indicates the use of IPE only in patients with TG levels ≥1.7 mmol/L (≥150 mg/dL), who are taking statins and who have established CV disease.1 Although this target population comes from the inclusion criteria of REDUCE-IT, it does not take into account the fact that CV disease risk reduction in that trial was independent of the patients’ baseline TG levels.3 Opening the label to all patients presenting as high risk would be something worth considering as more data accumulate, in order to support the dissociation of IPE treatment from TG levels. In any case, adding IPE to optimum statin treatment (administered either based on high absolute risk or as treatment of hyperlipidaemia) should remain the preferred strategy. Another interesting population that may benefit from IPE, could be those intolerant to statins who are at high risk based on either conventional risk calculators (e.g., QRISK®3, the European Society of Cardiology Systematic COronary Risk Estimation [ESC-SCORE2]) or enhanced risk calculators that use imaging to also take into account the residual inflammatory risk (e.g., CaRi-HEARTTM).9 Patients with diabetes could also be further investigated as a target population of IPE treatment,12 even if their absolute 10-year risk is low; this proposal was introduced based on the sensitivity analyses of the diabetic population within REDUCE-IT.13

Furthermore, IPE was proven to significantly reduce ischaemic events in the subpopulation of REDUCE-IT with a history of myocardial infarction (MI).14 To further explore the potential of IPE in reducing the risk of recurrent MI or ischaemic events in this population, future clinical trials should focus more on secondary prevention. Moreover, clinical trials that would select patients based on either vascular inflammatory status (using the FAI) or based on IPE/EPA levels15,16 would be informative.

IPE and other diseases with indirect cardiovascular implications

Autoimmune diseases

Chronic inflammatory/autoimmune diseases lead to increased CV disease risk.17–19 Recent evidence suggests that EPA may prevent or even treat autoimmune diseases such as systemic lupus erythematosus (SLE), multiple sclerosis, rheumatoid arthritis (RA) or even type 1 diabetes,20 as discussed below:

  • SLE. Multiple studies on SLE have demonstrated that omega-3 polyunsaturated fatty acids (n-3 PUFA) treatment may affect disease activity, improve endothelial function, and supress systemic inflammation.21–26
  • Multiple sclerosis. In cases of multiple sclerosis, n-3 PUFAs were able to promote remyelination; these protective and repairing effects were specifically related to EPA-derived metabolites and directly impact oligodendrocytes and neurons.27
  • Rheumatoid arthritis. In vitro studies have shown that exposure of T-cells from patients with RA to EPA and DHA inhibits the release of pro-inflammatory cytokines from these cells; therefore, n-3 PUFAs could potentially modulate inflammation and play a role in the treatment of RA.28
  • Inflammatory bowel disease. Inflammatory bowel disease (IBD) is often related to an increased level of n-6 PUFAs and consequent decreases of n-3 PUFAs, specifically, EPA.29

Given the role of all these inflammatory diseases in CV risk,30 it appears logical to assume that EPA, and specifically IPE, may have a role to play in preventing CV events in patients with autoimmune or inflammatory diseases.


REDUCE-IT came to change the landscape of pharmacological reduction of CV disease risk; IPE appears to provide an effective solution to improve CV outcomes, in addition to statin treatment. Although currently restricted to use in those patients with hypertriglyceridaemia on statins, it is clear that the beneficial effects of IPE are not only limited to this population. Future mechanistic studies are anticipated, which should shed light onto the exact mechanisms behind the risk reduction caused by this drug and support its broader use in both primary and secondary prevention.

Key messages

  • Investigating the mechanisms by which icosapent ethyl (IPE) reduces cardiovascular risk may lead to its broader use in preventive cardiovascular medicine
  • Upcoming studies will explore the responsiveness of cardiovascular inflammation to IPE
  • As more data accumulates we will better understand the relationship of IPE to triglyceride levels

Conflicts of interest

CA is founder, shareholder and director of Caristo Diagnostics, a CT image analysis spinout company from the University of Oxford. CA has received honoraria from Amarin. CA is chair of the British Atherosclerosis Society. LV: none declared.

Lucrezia Volpe
Clinical Research Fellow at the University of Oxford

Charalambos Antoniades
BHF Chair of Cardiovascular Medicine at the University of Oxford

Acute Multidisciplinary Imaging and Interventional Centre, Division of Cardiovascular Medicine, University of Oxford, Level 6 West Wing, John Radcliffe Hospital, Headington, Oxford OX3 9DU
([email protected])

Articles in this supplement

Triglyceride-rich lipoproteins and their role in cardiovascular disease
The evidence for fish oils and eicosapentaenoic acid in managing hypertriglyceridaemia
REDUCE-IT: findings and implications for practice


1. National Institute for Health and Care Excellence (NICE). Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides. Technology appraisal guidance [TA805]. Published: 13 July 2022. Available at: https://www.nice.org.uk/guidance/ta805/chapter/3-Committee-discussion (accessed 23 March 2023).

2. Wang X, Verma S, Mason RP, Bhatt DL. The road to approval: a perspective on the role of icosapent ethyl in cardiovascular risk reduction. Curr Diab Rep 2020;20. Published online: 23 October 2020. https://doi.org/10.1007/s11892-020-01343-7

3. Bhatt DL, Steg PG, Miller M, et al.; REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019;380:11–22. https://doi.org/10.1056/NEJMoa1812792

4. Ballantyne CM, Braeckman RA, Bays HE, et al. Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study). J Clin Lipidol 2015;9:377–83. https://doi.org/10.1016/j.jacl.2014.11.009

5. Bays HE, Ballantyne CM, Braeckman RA, Stirtan WG, Soni PN. Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies. Am J Cardiovasc Drugs 2013;13:37–46. https://doi.org/10.1007/s40256-012-0002-3

6. Slart RHJA, Glaudemans AWJM, Gheysens O, et al.; 4Is Cardiovascular Imaging: a joint initiative of the European Association of Cardiovascular Imaging (EACVI); European Association of Nuclear Medicine (EANM). Procedural recommendations of cardiac PET/CT imaging: standardization in inflammatory-, infective-, infiltrative-, and innervation (4Is)-related cardiovascular diseases: a joint collaboration of the EACVI and the EANM. Eur J Nucl Med Mol Imaging 2021;48:1016–39. https://doi.org/10.1007/s00259-020-05066-5

7. Antonopoulos AS, Sanna F, Sabharwal N, et al. Detecting human coronary inflammation by imaging perivascular fat. Sci Transl Med 2017;9:eaal2658. https://doi.org/10.1126/scitranslmed.aal2658

8. Oikonomou EK, Marwan M, Desai MY, et al. Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data. Lancet 2018;392:929–39. https://doi.org/10.1016/S0140-6736(18)31114-0

9. Klüner LV, Oikonomou EK, Antoniades C. Assessing cardiovascular risk by using the fat attenuation index in coronary CT angiography. Radiol Cardiothorac Imaging 2021;3:e200563. https://doi.org/10.1148/ryct.2021200563

10. Antoniades C, Antonopoulos AS, Deanfield J. Imaging residual inflammatory cardiovascular risk. Eur Heart J 2020;41:748–58. https://doi.org/10.1093/eurheartj/ehz474

11. lnabawi YA, Oikonomou EK, Dey AK, et al. Association of biologic therapy with coronary inflammation in patients with psoriasis as assessed by perivascular fat attenuation index. JAMA Cardiol 2019;4:885–91. https://doi.org/10.1001/jamacardio.2019.2589

12. Nichols GA, Philip S, Reynolds K, Granowitz CB, Fazio S. Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol. Diabetes Obes Metab 2019;21:366–71. https://doi.org/10.1111/dom.13537. Published online: 14 Oct 2018.

13. Brinton EA. Potential role for expanded use of icosapent ethyl in prevention of atherosclerotic cardiovascular disease in patients with diabetes. American College of Cardiology 2020. Available at: https://www.acc.org/latest-in-cardiology/articles/2020/05/18/08/26/potential-role-for-expanded-use-of-icosapent-ethyl (accessed 23 March 2023).

14. Gaba P, Bhatt DL, Steg PG, et al.; REDUCE-IT Investigators. Prevention of cardiovascular events and mortality with icosapent ethyl in patients with prior myocardial infarction. J Am Coll Cardiol 2022;79:1660–71. https://doi.org/10.1016/j.jacc.2022.02.035

15. Lázaro I, Rueda F, Cediel G, et al. Circulating omega-3 fatty acids and incident adverse events in patients with acute myocardial infarction. J Am Coll Cardiol 2020;76:2089–97. https://doi.org/10.1016/j.jacc.2020.08.073

16. Antiochos P, Ge Y. Effects of omega-3 fatty acids on ventricular remodeling and systemic inflammation after acute myocardial infarction. J Am Coll Cardiol 2021;77:1026. https://doi.org/10.1016/j.jacc.2020.11.071

17. Crowson CS, Liao KP, Davis JM 3rd, et al. Rheumatoid arthritis and cardiovascular disease. Am Heart J 2013;166:622–8. https://doi.org/10.1016/j.ahj.2013.07.010. Published online: 29 Aug 2013.

18. Tornvall P, Göransson A, Ekman J, Järnbert-Pettersson H. myocardial infarction in systemic lupus erythematosus: incidence and coronary angiography findings. Angiology 2021;72:459–64. https://doi.org/10.1177/0003319720985337. Published online: 8 Jan 2021.

19. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;55:829–35. https://doi.org/10.1016/j.jaad.2006.08.040. Published online: 26 Sep 2006.

20. Crupi R, Cuzzocrea S. Role of EPA in inflammation: mechanisms, effects, and clinical relevance. Biomolecules 2022;12:242. https://doi.org/10.3390/biom12020242

21. Arriens C, Hynan LS, Lerman RH, Karp DR, Mohan C. Placebo-controlled randomized clinical trial of fish oil’s impact on fatigue, quality of life, and disease activity in systemic lupus erythematosus. Nutr J 2015;14:82. https://doi.org/10.1186/s12937-015-0068-2

22. Elkan AC, Anania C, Gustafsson T, Jogestrand T, Hafström I, Frostegård J. Diet and fatty acid pattern among patients with SLE: associations with disease activity, blood lipids and atherosclerosis. Lupus 2012;21:1405–11. https://doi.org/10.1177/0961203312458471. Published online: 28 Aug 2012.

23. Duffy EM, Meenagh GK, McMillan SA, Strain JJ, Hannigan BM, Bell AL. The clinical effect of dietary supplementation with omega-3 fish oils and/or copper in systemic lupus erythematosus. J Rheumatol 2004;31:1551–6.

24. Das UN. Beneficial effect of eicosapentaenoic and docosahexaenoic acids in the management of systemic lupus erythematosus and its relationship to the cytokine network. Prostaglandins Leukot Essent Fatty Acids 1994;51:207–13. https://doi.org/10.1016/0952-3278(94)90136-8

25. Westberg G, Tarkowski A. Effect of MaxEPA in patients with SLE. A double-blind, crossover study. Scand J Rheumatol 1990;19:137–43. https://doi.org/10.3109/03009749009102117

26. Clark WF, Parbtani A, Huff MW, Reid B, Holub BJ, Falardeau P. Omega-3 fatty acid dietary supplementation in systemic lupus erythematosus. Kidney Int 1989;36:653-60. https://doi.org/10.1038/ki.1989.242

27. Li X, Bi X, Wang S, Zhang Z, Li F, Zhao AZ. Therapeutic potential of ω-3 polyunsaturated fatty acids in human autoimmune diseases. Front Immunol 2019;10:2241. https://doi.org/10.3389/fimmu.2019.02241

28. Kremer JM, Lawrence DA, Jubiz W, et al. Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects. Arthritis Rheum 1990;33:810–20. https://doi.org/10.1002/art.1780330607

29. Marton LT, Goulart RA, Carvalho ACA, Barbalho SM. Omega fatty acids and inflammatory bowel diseases: an overview. Int J Mol Sci 2019;20:4851. https://doi.org/10.3390/ijms20194851

30. Roifman I, Beck PL, Anderson TJ, Eisenberg MJ, Genest J. Chronic inflammatory diseases and cardiovascular risk: a systematic review. Can J Cardiol 2011;27:174–82. https://doi.org/10.1016/j.cjca.2010.12.040


Medical knowledge is constantly changing. As new information becomes available, changes in treatment, procedures, equipment and the use of drugs become necessary. The editors/authors/contributors and the publishers Medinews (Cardiology) Ltd have taken care to ensure that the information given in this text is accurate and up to date at the time of publication.

Readers are strongly advised to confirm that the information, especially with regard to drug usage, complies with the latest legislation and standards of practice. Medinews (Cardiology) Limited advises healthcare professionals to consult up-to-date Prescribing Information and the full Summary of Product Characteristics available from the manufacturers before prescribing any product. Medinews (Cardiology) Limited cannot accept responsibility for any errors in prescribing which may occur.

The opinions, data and statements that appear are those of the contributors. The publishers, editors, and members of the editorial board do not necessarily share the views expressed herein. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the publisher, editors, the editorial board or their agents or employees is accepted for the consequences of any inaccurate or misleading information.

© Medinews (Cardiology) Ltd 2023. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the publishers, Medinews (Cardiology) Ltd. It shall not, by way of trade or otherwise, be lent, re-sold, hired or otherwise circulated without the publisher’s prior consent.